First-line Options in Metastatic Renal Cell Carcinoma

Robert Motzer, MD; Chung-Han Lee, MD, PhD


September 09, 2022

Treatment options in metastatic renal cell carcinoma (RCC) have expanded dramatically in recent years, from high-dose interleukin 2 to targeted therapies such as vascular endothelial growth factor receptor (VEGFR) inhibitors to the inclusion of checkpoint inhibitor immunotherapy.

Oncologist Dr Robert Motzer is joined by his colleague Dr Chung-Han Lee, both from Memorial Sloan Kettering Cancer Center in New York, to discuss optimal first-line treatment therapy for their patients with RCC, including a new standard of care consisting of combination tyrosine kinase inhibitor (TKI) and immunotherapy. They also discuss risk stratification and management considerations that range from comorbidities, caregiver availability, and efficacy vs toxicity that factor into the choice of therapy for an individual patient.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.